HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. El-Serag HB, Jin Q, Tayob N, Salem E, et al. Hepatology 2025;81:465-475.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

El-Serag HB, Jin Q, Tayob N, Salem E, et al. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology 2025;81:465-475.
PMID: 38899967